
- MHE August 2023
- Volume 33
- Issue 8
A Wave of New Treatments, a Tsunami of Ultrahigh Prices
Charging more than $2 million for a single treatment was once unthinkable, but no more.
Charging more than $2 million for a single treatment was once unthinkable, but no more. Today’s gene therapies and other innovative medicines for rare diseases come with price tags that stagger the mind, and despite continuing public controversy over drug pricing, they’re not necessarily unfair.
Still, that leaves the question of how a health plan today can absorb even a single claim without looking like the misshapen boa constrictor in “The Little Prince” who famously — and visibly — had swallowed an elephant.
Related:
Below are just a few of the recent FDA-approved therapies with staggering price tags.
Articles in this issue
almost 3 years ago
Between the Lines: Bempedoic Acidalmost 3 years ago
As TEFCA Cohorts Take Shape, Stakeholders Now Must Show its Potentialalmost 3 years ago
Healthcare Split on Noncompete Agreementsalmost 3 years ago
Why DIY? Hospitals Are Outsourcing Clinical, Nonclinical Servicesalmost 3 years ago
Response Letters, Alzheimer’s Disease Drugs and Mounjaroalmost 3 years ago
The Great Disenrollmentalmost 3 years ago
When Drugs Became Ultra-Ultra Expensivealmost 3 years ago
Adding SERDs to the Adjuvant Armamentarium





















